BioSpace News Archive

Protech Home Medical Corp., a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care‎, is pleased to announce record preliminary financial results for the third quarter of 2020, ending June 30, 2020.

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced updates to its clinical programs, the neoantigen vaccine GEN-009 and the neoantigen cell therapy, GEN-011. GEN-009 On July 30, 2020, the Company will share initial clinical data on the first 5 patients from Part B of the ongoing Phase 1/2a clinical trial exploring the combination of GEN-009 and imm

Paradromics, Inc, an Austin, TX-based startup, just unveiled the largest ever electrical recording of cortical activity, using the highest capacity neural recording system.

Fosmanogepix met primary efficacy endpoint and demonstrated favorable safety profile in first-line treatment of invasive Candida infections

PolarityTE, Inc. (Nasdaq: PTE) announced that data from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized controlled trial (RCT) entitled “SkinTE™ in the Treatment of Diabetic Foot Wounds” will be featured in a poster presentation at the Symposium on Advanced Wound Care (SAWC) Spr

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into definitive agreements with existing institutional investors and other accredited investors, for the purchase and sale of 2,581,867 shares of its common stock, at a purchase price of $2.3825 per share, in a registered direct offering price

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the first quarter ended June 30, 2020 on Wednesday, July 29th, 2020 after the Board Meeting.

IQVIA™ (NYSE: IQV) today announced it is joining forces with JDRF , the leading global organization funding type 1 diabetes (T1D) research, to use non-identified patient-level, real world data and analytics to address unmet n

- D ata show a 90% decrease in mortality with Allocetra TM treatment in a murine cecal ligation and puncture severe sepsis model Nes Ziona, Israel, July 20, 2020

Possible Phase 3 Would Increase Total Project Revenue to $6.7 million